Deciding to participate in a clinical trial is a personal decision that can potentially have a profound beneficial impact on a patient’s cancer journey. Although many patients may be interested in participating in a cutting-edge clinical trial, questions around where to begin, eligibility or even making sense of scientific descriptions can pose a challenge.
TOI’s Innovative Clinical Research Institute (ICRI) team has made clinical trial participation more accessible than ever. Below are just a few of the many progressive clinical studies being conducted at ICRI:
HiberCell, PGG-MEL2021
- Cancer Type Targeted: Melanoma
- Who’s Eligible: Patients with Stage III, Resectable Melanoma
- Description/Objective: To determine the pathological response rate in the surgically removed specimen after completion of therapy given with Imprime PGG plus pembrolizumab vs pembrolizumab monotherapy.
- Clinical Trial Phase: II*
- *If a new treatment is found to be safe in phase I clinical trials, a phase II clinical trial is done to see if it works in certain types of cancer for a specified duration.¹ Benefits during this phase can include improvement in quality of life.
- Minimum Age Requirement: 18 years or older
- Estimated Study Duration: 2 years (Through 2023)
- Location(s): Downey, Glendale, Long Beach, Whittier
AnHeart Therapeutics Inc. AB-106-G208
- Cancer Type Targeted: Lung Cancer (Non-small cell lung cancer) or other solid tumors
- Who’s Eligible: Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
- Description/Objective: To evaluate safety and efficacy of the anti-cancer drug, Taletrectinib, in subjects with NSCLC. Patients will continue with treatment and tumor response will be evaluated on a regular basis until progression of disease is determined by the investigator. Long-term survival follow up will be conducted as well.
- Clinical Trial Phase: II
- Minimum Age Requirement: 18 years or older
- Estimated Study Duration: Up to 4 years
- Location(s): Glendale, Long Beach, Whittier, Santa Ana
Incyte Corporation, INCMOR0208-301
- Cancer Type Targeted: Lymphoma
- Who’s Eligible: Patients with Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
- Description/Objective: This Phase 3 double-blind, placebo-controlled, randomized study is designed to investigate whether anti-cancer drugs, Tafasitamab and Lenalidomide – as an add-on to Rituximab, provides improved clinical benefit; as compared to Lenalidomide as an add-on to Rituximab in patients with the targeted cancers.
- Clinical Trial Phase: III*
- Treatments that have been shown to work in phase II clinical trials must succeed in one more phase before they’re approved for general use. Phase III clinical trials compare the safety and effectiveness of the new treatment against the current standard treatment.²
- Minimum Age Requirement: 18 years or older
- Estimated Study Duration: Up to 6 years
- Location(s): Glendale, Long Beach, Whittier, Santa Ana, and Pasadena
It’s best to speak to a primary care provider or oncologist before making the decision to participate in a clinical trial. By participating in a clinical trial, patients are not only able to help researchers learn more about treatment, but can improve the quality of life and care for future patients.
For a complete list of clinical trials at ICRI, click here.
References:
1 & 2: Types of Phases and Clinical Trials – American Cancer Society
Want more information on clinical trials?
Discover a clinical trial that might be right for you
